Med Ed Report briefs

Share this article:
A ProPublica analysis of drug company disclosures in Minnesota found multiple examples in which firms reported either inaccurate or inappropriate payment information to the state. In some cases, according to the December analysis, companies understated the extent of fees cited on their own websites.

The Alliance for CME launched a Lifelong Learning series on XM Satellite Radio in which CME thought leaders discuss issues related to methodology, effectiveness and funding, among other topics. The programs will air over six weeks on channel 160 and are hosted by Prova Education's Lawrence Sherman.

Accredited med ed provider Med-IQ said 361 clinicians have completed its PI CME and that more than 11,440 participants have enrolled. The firm has successfully launched and implemented more than 10 AMA-standardized, certified PI CME activities since 2008 in a wide range of therapeutic and clinical areas, it said.

The ACCME named Dr. Richard Reiling and Sandra Norris 2011 chair and vice chair, respectively, of its board of directors. Two other new board members were elected, as well. Names of the officials were announced in a December statement by ACCME.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?